Preclinical Research
and Regulatory Services
Our preclinical support begins with millions of healthy and disease state biospecimens along with the lab capabilities to investigate disease biology and target expression, and to develop complex biomarker assays that can be moved into the clinical phase. We also support development of clinical biomarker strategies, as well and companion diagnostics programs.
A range of solutions to chaperone your project to the clinical phase
-
Explore
Biospecimens
- 7M+ Liquid Biospecimens
- 3M+ Tissue Biospecimens
- Custom Collections
-
Explore
Biomarker Discovery and Target Validation
Identification and validation of therapeutic targets for small molecule, large molecule, and advanced therapies -
Explore
Specialty Assay Development
Assay development and validation for any tissue type, with 7 global labs and technologies to generate data from any sample type
-
Explore
Biomarker Strategy
Development of biomarker plans to ensure successful clinical trial initiation
-
Explore
Companion Diagnostics Program Development
- Early planning to develop biomarkers into clinical trial assays
- Mapping of specific regulatory requirements
Biospecimens to support preclinical development of therapeutics and diagnostics
With a biorepository of over 10 million healthy and disease-state biospecimens, along with the ability to prospectively collect virtually any specimens needed, Precision can support your therapeutic and diagnostic research needs.
Explore some of the biospecimen types available:
Biomarker discovery and target validation
Effectively identifying and validating therapeutic targets and biomarkers are key to effective precision therapeutic development. Precision for Medicine provides a range of human tissue-based research services including IHC, mIF, cell-based assays, and genomics.
We specialize in utilizing these services for small molecule, large molecule, and advanced therapeutics (gene and cell therapies) to help you understand target expression and localization, determine tumor biology and cellular interplay, and characterize novel therapeutic entities.
Specialty assay development
Precision supports preclinical development through biomarker assay development, with a focus on large molecule bioanalysis and immunogenicity assays. Examples of our expertise include:- Tissue cross-reactivity
- Immunogenicity
- Neutralizing antibody/total antibody (NAb/Tab) assays
- PK Assays
- Tissue analysis via Immunohistochemistry and Multiplex Immunofluorescence
- Sensitive analyte measurement using enzyme-linked immunosorbent assays (ELISAs) and Luminex, MesoScale Discovery (MSD), and SIMOA platforms
- Viral tissue distribution in gene therapies via ddPCR, qPCR
- Assessment of gene editing accuracy and specificity in gene editing therapies via NGS
Biomarker strategy: planning for biomarker analysis in clinical trials
-
Informed Consent
Informed Consent
-
Sample Kits
Sample Kits
-
eCRF
eCRF
-
Site Budgets
Site Budgets
-
Data Management
Data Management
Companion diagnostics program development
Precision’s unmatched experience in diagnostic development takes your product from bench to bedside, starting in at the preclinical phase.
- Development of biomarker assays
- Indications and claims development
- Product design considerations
- Regulatory pathway identification (eg, FDA/LDT, product class)
- POC vs. laboratory vs home use
- CLIA/QMS compliance strategy